FDA revokes EUA for monoclonal antibody therapy ...
The FDA revoked the EUA for bamlanivimab alone due to increased SARS-CoV-2 variants resistant to it, making its risks outweigh benefits. Alternative monoclonal antibody therapies remain authorized. The FDA emphasizes the importance of using therapies effective against all variants and commits to monitoring and communicating on variant impacts.
Reference News
FDA revokes EUA for monoclonal antibody therapy ...
The FDA revoked the EUA for bamlanivimab alone due to increased SARS-CoV-2 variants resistant to it, making its risks outweigh benefits. Alternative monoclonal antibody therapies remain authorized. The FDA emphasizes the importance of using therapies effective against all variants and commits to monitoring and communicating on variant impacts.